As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing ...
LUND, SE / ACCESS Newswire / July 17, 2026 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the ...
Kelun-Biotech, listed under stock code 6990.HK, announced its Phase III OptiTROP-Lung06 trial of sac-TMT combined with ...
The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...
KEYTRUDA as Monotherapy Significantly Improved PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer Compared ...
Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.
Patients with cancer, diabetes, haemophilia, Parkinson's disease and other serious illnesses are forced to rely on costly ...
US FDA approves Pfizer & Astellas’ Padcev plus Keytruda as neoadjuvant and adjuvant treatment for MIBC regardless of cisplatin eligibility: New York Monday, July 13, 2026, 13:00 ...
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...
Morning Overview on MSN
Regulators cleared Keytruda with chemo before and after surgery for aggressive bladder cancer
Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the ...
MedPage Today on MSN
Biomarkers for Esophageal Cancer Continue to Evolve
Recently validated markers have helped improve treatment but more are needed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results